food companies are joining in on this latest trend by developing products targeted toward GLP-1 users. Related: Major food ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

The US Food and Drug Administration (FDA) has issued warning letters to four companies selling unapproved glucagon-like peptide-1 receptor agonist (GLP-1RA) products, as the agency continues its ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

At the moment that’s uncommon because diabetics and their carers are often reluctant to prepare current glucagon products so they generally need to be administered by a healthcare professional.

Both products are priced at a similar level to the glucagon injection kits available on the market, with a list price of $280 per dose, and in the US Xeris has partnered with Amazon’s PillPack ...

The rise in medication usage for weight loss unlocks opportunities for innovation in health-focused products and ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...